New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
10:31 EDTNPSP, CLDX, INCY, GILDOppenheimer sees opportunities following biotech decline
After biotech stocks declined on Friday, Oppenheimer believes that the weakness in the sector has created a buying opportunity. The firm identifies Celldex (CLDX), Incyte (INCY) and NPS Pharmaceuticals (NPSP) as interesting biotech names. WHAT'S NEW: On Friday, biotech investors were concerned by a letter sent by several members of Congress to Gilead (GILD) regarding the price of its Hepatits C drug, Sovaldi, Oppenheimer analyst Dr. Boris Peaker wrote in a note to investors. However, the biotech sector's strong pricing power is unlikely to be curtailed In the near-term, Peaker believes. Since competing drugs are priced at similar levels as Sovaldi, Congress would have to lower the drugs' prices through legislation, which is unlikely to occur, Peaker forecast. Celldex's stock is attractive since its top drugs are very innovative, face no direct competition, are wholly owned by the company, and are unlikely to have biosimilars, Peaker wrote. Meanwhile, Incyte's Jakafi, a treatment for Myelofibrosis, could be used as a treatment for solid tumors following additional studies, the analyst forecast. Additionally, Jakafi is "highly innovative," and has not experienced any pricing pressures, the analyst stated. NPS' two major products, Gattex and Natpara, are both orphan drugs that provide significant benefits to patients and do not have any looming competition, Peaker said, adding that Gattex's U.S. sales should continue to be strong. Gattex is used to treat short bowel syndrome, while Natpara is supposed to treat hypoparathyroidism. Oppenheimer has Outperform ratings on all the stocks named. PRICE ACTION: In mid-morning trading, Gilead fell 2.3% to $70.40, Celldex gave back 6.6% to $20.10, Incyte tumbled 5.8% to $56, and NPS sank 5.8% to $28.35.
News For GILD;CLDX;NPSP;INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 1, 2015
08:07 EDTCLDXCelldex appoints Richard Wright as Chief Commercial Officer
Celldex Therapeutics announced the promotion of Richard Wright, Ph.D. to SVP and the newly created position of Chief Commercial Officer. Dr. Wright was previously Vice President of Commercial Operations at Celldex and brings nearly 25 years of industry experience, including the commercialization of six successful drug therapies. As Chief Commercial Officer, Dr. Wright is responsible for developing global business strategy and building the infrastructure required to support commercialization of Celldex's cancer immunotherapy pipeline.
June 30, 2015
11:58 EDTGILDStocks with call strike movement; GILD YHOO
Gilead (GILD) November 130 call option implied volatility increased 2% to 28, Yahoo (YHOO) October 46 call option implied volatility decreased 2% to 29 according to IVolatility.
09:35 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB GILD BABA BAC MU WYNN MSFT NFLX
07:32 EDTGILDJuno pact leaves Celgene set for growth past Revlimid, says Deutsche Bank
Subscribe for More Information
June 29, 2015
16:30 EDTGILDFDA sued by advocacy groups for Gilead Hep-C drug trial data, Reuters says
Subscribe for More Information
08:26 EDTCLDXCelldex announces independent DSMB recommends continuation of Rintega study
Subscribe for More Information
June 25, 2015
09:34 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB NFLX AMZN BAC CVX TWTR INTC GILD BBBY
07:11 EDTINCYImmunoVaccine announces collaboration with Incyte
Subscribe for More Information
June 23, 2015
14:10 EDTGILDGilead price target raised to $150 from $130 at Argus
Subscribe for More Information
07:25 EDTINCYPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
09:40 EDTGILDActive equity options trading on open
Subscribe for More Information
June 19, 2015
16:00 EDTGILDOptions Update; June 19, 2015
iPath S&P 500 VIX Short-Term Futures up 11c to 18.21, Option volume leaders: AAPL TWTR BAC T FB GILD NFLX BABA AAL MU AMZN
07:05 EDTINCYIncyte says EVP, Chief Commercial Officer Jim Daly to leave at end of June
Subscribe for More Information
06:40 EDTGILDPatent linked to Gilead's Solvadi rejected by China, Reuters reports
Subscribe for More Information
June 18, 2015
11:53 EDTINCYIncyte management to meet with SunTrust
Subscribe for More Information
07:36 EDTGILDReceptos remains an attractive takeover candidate, says Leerink
Subscribe for More Information
06:55 EDTINCYIncyte management to meet with JMP Securities
Meetings to be held in New York on June 18 and in Boston on June 19 hosted by JMP Securities.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use